Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.uca.edu.ar/handle/123456789/8802
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Cardinali, Daniel Pedro | es |
dc.date.accessioned | 2019-10-01T17:00:01Z | - |
dc.date.available | 2019-10-01T17:00:01Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Cardinali DP. Melatonin : clinical perspectives in neurodegeneration [en línea]. Frontiers in Endocrinology. 2019;10. doi:10.3389/fendo.2019.00480 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/8802 | es |
dc.identifier.issn | 1664-2392 | - |
dc.identifier.uri | https://repositorio.uca.edu.ar/handle/123456789/8802 | - |
dc.description.abstract | Abstract: Prevention of neurodegenerative diseases is presently a major goal for our Society and melatonin, an unusual phylogenetically conserved molecule present in all aerobic organisms, merits consideration in this respect. Melatonin combines both chronobiotic and cytoprotective properties. As a chronobiotic, melatonin can modify phase and amplitude of biological rhythms. As a cytoprotective molecule, melatonin reverses the low degree inflammatory damage seen in neurodegenerative disorders and aging. Low levels of melatonin in blood characterizes advancing age. In experimental models of Alzheimer's disease (AD) and Parkinson's disease (PD) the neurodegeneration observed is prevented by melatonin. Melatonin also increased removal of toxic proteins by the brain glymphatic system. A limited number of clinical trials endorse melatonin's potentiality in AD and PD, particularly at an early stage of disease. Calculations derived from animal studies indicate cytoprotective melatonin doses in the 40-100 mg/day range. Hence, controlled studies employing melatonin doses in this range are urgently needed. The off-label use of melatonin is discussed. | es |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Frontiers | es |
dc.rights | Acceso abierto | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.source | Frontiers in Endocrinology. 2019;10 | es |
dc.subject | ENFERMEDAD DE ALZHEIMER | es |
dc.subject | ENFERMEDAD DE PARKINSON | es |
dc.subject | ENFERMEDADES NEUROGENERATIVAS | es |
dc.subject | ENVEJECIMIENTO | es |
dc.subject | MELATONINA | es |
dc.subject | NEURODEGENERACION | es |
dc.subject | ESTRES OXIDATIVO | es |
dc.title | Melatonin : clinical perspectives in neurodegeneration | es |
dc.type | Artículo | es |
dc.identifier.doi | 10.3389/fendo.2019.00480 | - |
dc.identifier.pmid | 31379746 | - |
uca.disciplina | MEDICINA | es |
uca.issnrd | 1 | es |
uca.affiliation | Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina | es |
uca.version | publishedVersion | es |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.fulltext | With Fulltext | - |
crisitem.author.dept | Consejo Nacional de Investigaciones Científicas y Técnicas | - |
crisitem.author.dept | Instituto de Investigaciones Biomédicas - BIOMED | - |
crisitem.author.dept | Facultad de Ciencias Médicas | - |
crisitem.author.orcid | 0000-0002-0813-9088 | - |
crisitem.author.parentorg | Facultad de Ciencias Médicas | - |
crisitem.author.parentorg | Pontificia Universidad Católica Argentina | - |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
melatonin-clinical-perspectives-neurodegeneration.pdf | 622,58 kB | Adobe PDF | Visualizar/Abrir |
Visualizaciones de página(s)
213
comprobado en 25-sep-2024
Descarga(s)
208
comprobado en 25-sep-2024
Google ScholarTM
Consultar
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons